1
Clinical Trials associated with Gag 267-274 peptide vaccine(Mayo Clinic) / CompletedEarly Phase 1IIT Peptide Vaccine With Resiquimod as an Immune Modulator for Patients With Resected Melanoma: A Pilot Study
This pilot clinical trial studies vaccine therapy and resiquimod in treating patients with stage II-IV melanoma that has been removed by surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cell tumor cells. Biological therapies, such as resiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether Gag:267-274 peptide vaccine and resiquimod are more effective when given together or separately
100 Clinical Results associated with Gag 267-274 peptide vaccine(Mayo Clinic)
100 Translational Medicine associated with Gag 267-274 peptide vaccine(Mayo Clinic)
100 Patents (Medical) associated with Gag 267-274 peptide vaccine(Mayo Clinic)
100 Deals associated with Gag 267-274 peptide vaccine(Mayo Clinic)